潜能未定的克隆性造血：关于衰老、炎症与动脉粥样硬化的新认识

颜红兵; 陈润真

doi:10.13201/j.issn.1001-1439.2024.05.002

潜能未定的克隆性造血：关于衰老、炎症与动脉粥样硬化的新认识

颜红兵^1,2, ,,
陈润真¹

- 1.
  国家心血管病中心北京协和医学院中国医学科学院阜外医院冠心病中心(北京，100037)
- 2.
  中国医学科学院阜外医院深圳医院
基金项目:
国家自然科学基金(No：81970308)；深圳市医疗卫生三名工程(No：SZSM201911017)；深圳市医学重点学科建设经费(No：SZXK001)

详细信息

通讯作者: 颜红兵，E-mail：hbyanfuwai@aliyun.com

中图分类号: R543

收稿日期: 2024-04-08

刊出日期: 2024-05-13

Clonal hematopoiesis of indeterminate potential: insights about aging, inflammation and atherosclerosis

YAN Hongbing^1,2, ,,
CHEN Runzhen¹

- 1.
  Coronary Artery Diseases Center, Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100037, China
- 2.
  Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences

More Information

Corresponding author: YAN Hongbing, Email: hbyanfuwai@aliyun.com

Received Date: 08 April 2024

Publish Date: 13 May 2024

摘要

摘要: 潜能未定的克隆性造血(clonal hematopoiesis of indeterminate potential，CHIP)是一种由年龄相关体细胞突变所致、致病潜能未定的造血干细胞扩增。新近研究显示，CHIP与动脉粥样硬化疾病的发生密切相关，CHIP相关突变(如DNMT3A、TET2、JAK2等)可激活炎症相关信号通路(如NLRP3、AIM2炎症小体等)，诱发局部炎症反应，促进动脉粥样硬化斑块的形成，对于抗炎药物的开发与应用有重要意义。本文拟从流行病学、分子机制和临床意义3个方面，探讨CHIP与衰老、炎症和动脉粥样硬化发病机制的关系。
- 潜能未定的克隆性造血 /
- 动脉粥样硬化 /
- 衰老 /
- 炎症
Abstract: Clonal hematopoiesis of indeterminate potential(CHIP) refers to clonal hematopoiesis driven by age-related somatic mutations with undetermined potential for hematologic malignancy. Recent studies suggest that CHIP plays an important role in the pathogenesis of atherosclerosis, as mutations of CHIP genes(e.g., DNMT3A, TET2, JAK2) could activate inflammation signal pathways(e.g., NLRP3, AIM2 inflammasomes), induce regional inflammatory response, thereby promoting the formation of atherosclerotic plaques, for which anti-inflammatory medications could be effective and of great interest. The current review aims to discuss the interactions between CHIP, aging, inflammation and atherosclerosis from the perspectives of epidemiology, molecular mechanistic and clinical practice.
- clonal hematopoiesis of indeterminate potential /
- atherosclerosis /
- aging /
- inflammation

HTML全文

参考文献(26)

[1]	Polizio AH, Park E, Walsh K. Clonal hematopoiesis: connecting aging and inflammation in atherosclerosis[J]. Curr Atherosclero Rep, 2023, 25(3): 105-111. doi: 10.1007/s11883-023-01083-5
[2]	Khetarpal SA, Qamar A, Bick AG, et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD[J]. J Am Coll Cardiol, 2019, 74(4): 578-586. doi: 10.1016/j.jacc.2019.05.045
[3]	Libby P, Sidlow R, Lin AE, et al. Clonal hematopoiesis[J]. J Am Coll Cardiol, 2019, 74(4): 567-577. doi: 10.1016/j.jacc.2019.06.007
[4]	Jaiswal S. Clonal hematopoiesis and nonhematologic disorders[J]. Blood, 2020, 136(14): 1606-1614.
[5]	Evans MA, Sano S, Walsh K. Cardiovascular disease, aging, and clonal hematopoiesis[J]. Annu Rev Pathol, 2020, 15: 419-438. doi: 10.1146/annurev-pathmechdis-012419-032544
[6]	Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential(CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease[J]. J Mol Cell Cardiol, 2021, 161: 98-105. doi: 10.1016/j.yjmcc.2021.07.004
[7]	Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence[J]. N Engl J Med, 2014, 371(26): 2477-2487. doi: 10.1056/NEJMoa1409405
[8]	Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med, 2014, 371(26): 2488-2498. doi: 10.1056/NEJMoa1408617
[9]	Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease[J]. N Engl J Med, 2017, 377(2): 111-121. doi: 10.1056/NEJMoa1701719
[10]	Bhattacharya R, Bick AG. Clonal hematopoiesis of indeterminate potential: an expanding genetic cause of cardiovascular disease[J]. Curr Atherosclero Rep, 2021, 23(11): 66. doi: 10.1007/s11883-021-00966-9
[11]	Haring B, Wissel S, Manson JE. Somatic mutations and clonal hematopoiesis as drivers of age-related cardiovascular risk[J]. Curr Cardiol Rep, 2022, 24(8): 1049-1058. doi: 10.1007/s11886-022-01724-2
[12]	Cobo I, Tanaka T, Glass CK, et al. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease[J]. Curr Opin Hematol, 2022, 29(1): 1-7. doi: 10.1097/MOH.0000000000000688
[13]	Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 Inflammasome[J]. J Am Coll Cardiol, 2018, 71(8): 875-886. doi: 10.1016/j.jacc.2017.12.037
[14]	Zekavat SM, Viana-Huete V, Matesanz N, et al. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease[J]. Nat Cardiovasc Res, 2023, 2(2): 144-158. doi: 10.1038/s44161-022-00206-6
[15]	Bick AG, Pirruccello JP, Griffin GK, et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis[J]. Circulation, 2020, 141(2): 124-131. doi: 10.1161/CIRCULATIONAHA.119.044362
[16]	Stein A, Metzeler K, Kubasch AS, et al. Clonal hematopoiesis and cardiovascular disease: deciphering interconnections[J]. Basic Res in Cardiol, 2022, 117(1): 5. doi: 10.1007/s00395-022-00912-z
[17]	Abplanalp WT, Cremer S, John D, et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure[J]. Circ Res, 2021, 128(2): 216-228. doi: 10.1161/CIRCRESAHA.120.317104
[18]	Sano S, Oshima K, Wang Y, et al. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease[J]. Circ Res, 2018, 123(3): 335-341. doi: 10.1161/CIRCRESAHA.118.313225
[19]	Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice[J]. Science, 2017, 355(6327): 842-847. doi: 10.1126/science.aag1381
[20]	Fidler TP, Xue C, Yalcinkaya M, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis[J]. Nature, 2021, 592(7853): 296-301. doi: 10.1038/s41586-021-03341-5
[21]	Dotan I, Yang J, Ikeda J, et al. Macrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux[J]. Commun Biol, 2022, 5(1): 132. doi: 10.1038/s42003-022-03078-5
[22]	Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. doi: 10.1056/NEJMoa1707914
[23]	Svensson EC, Madar A, Campbell CD, et al. TET2-driven clonal hematopoiesis and response to canakinumab[J]. JAMA Cardiology, 2022, 7(5): 521-528. doi: 10.1001/jamacardio.2022.0386
[24]	Hafiane A, Daskalopoulou SS. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis[J]. Pharmacol Res, 2022, 178: 106157. doi: 10.1016/j.phrs.2022.106157
[25]	Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26): 2497-2505. doi: 10.1056/NEJMoa1912388
[26]	Tall AR, Bornfeldt KE. Inflammasomes and atherosclerosis: a mixed picture[J]. Circ Res, 2023, 132(11): 1505-1520. doi: 10.1161/CIRCRESAHA.123.321637